Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$45.85 USD

45.85
11,933,398

+0.45 (0.99%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $45.75 -0.10 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Arpita Dutt headshot

Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved

by Arpita Dutt

This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.

    Zacks Equity Research

    Infinity Pharma Focuses on Cancer Drug: Competition Looms

    by Zacks Equity Research

    We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.

      Zacks Equity Research

      Bristol-Myers Squibb and CytomX Therapeutics Extend Deal

      by Zacks Equity Research

      Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.

        Zacks Equity Research

        6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017

        by Zacks Equity Research

        Glaxo carries a Zacks Rank #2 (Buy).

          Zacks Equity Research

          Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat

          by Zacks Equity Research

          Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.

            Sweta Killa headshot

            Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs

            by Sweta Killa

            President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.

              Zacks Equity Research

              Repros (RPRX) Q4 Earnings: What's in Store for the Stock?

              by Zacks Equity Research

              Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.

                Zacks Equity Research

                Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?

                by Zacks Equity Research

                Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.

                  Zacks Equity Research

                  AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?

                  by Zacks Equity Research

                  AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.

                    Zacks Equity Research

                    What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

                    by Zacks Equity Research

                    Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.

                      Zacks Equity Research

                      Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?

                      by Zacks Equity Research

                      Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.

                        Zacks Equity Research

                        Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4

                        by Zacks Equity Research

                        Nektar Therapeutics (NKTR) reported loss of 28 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of loss of 26 cents.

                          Zacks Equity Research

                          Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4

                          by Zacks Equity Research

                          Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.

                            Zacks Equity Research

                            Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?

                            by Zacks Equity Research

                            Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.

                              Zacks Equity Research

                              Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y

                              by Zacks Equity Research

                              Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.

                                Zacks Equity Research

                                Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?

                                by Zacks Equity Research

                                Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Arpita Dutt headshot

                                  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

                                  by Arpita Dutt

                                  Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.

                                    Joseph Lu headshot

                                    Bristol Myers' Future Unsure as Carl Icahn Takes Stake

                                    by Joseph Lu

                                    Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?

                                      Zacks Equity Research

                                      Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

                                      by Zacks Equity Research

                                      Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

                                        Joseph Lu headshot

                                        Can Carl Icahn Save Bristol Myers Squibb?

                                        by Joseph Lu

                                        Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.

                                          Arpita Dutt headshot

                                          Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ

                                          by Arpita Dutt

                                          The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi

                                            by Arpita Dutt

                                            Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.

                                              Zacks Equity Research

                                              Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

                                              by Zacks Equity Research

                                              Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

                                                Sweta Killa headshot

                                                Q4 Earnings Faring Well for Pharma ETFs

                                                by Sweta Killa

                                                Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.

                                                  Zacks Equity Research

                                                  Portola, HealthCare Royalty Partners Ink $150 Million Deal

                                                  by Zacks Equity Research

                                                  Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.